TB patient whose sputum smear or culture is positive at month 5 or later during treatment

Treatment terminated or need for permanent regimen change of at least two anti-TB drugs because of: lack of conversion by the end of the intensive phase, or bacteriological reversion in the continuation phase after conversion to negative, or evidence of additional acquired resistance to fluoroquinolones or second-line injectable drugs, or adverse drug reactions (ADRs)

In the United States, it is defined as continuously or recurrently positive cultures after 4 months (5 months in Europe and WHO guidelines) of treatment in a patient receiving appropriate chemotherapy

Continued or recurrent positive cultures after 4 months of treatment in patients in whom medication ingestion was assured

Person with bacteriologically confirmed tuberculosis who was smear-positive (or culture-positive) at 5 months or later of treatment (confirmed by a second specimen

Patient whose sputum smear or culture is positive at 5 months or later during treatment. Also included in this definition are patients found to harbour a multidrug-resistant (mdr) strain at any point of time during the treatment, whether they are smear-negative or -positive

Presence of a positive mycobacterial culture from at least one specimen beginning at a specified month

Treatment will be considered to have failed if two or more of the five cultures recorded in the final 12 months are positive, or if any one of the final three cultures is positive. Treatment will also be considered to have failed if a clinical decision has been made to terminate treatment early due to poor response or adverse events

Ongoing sputum culture positivity, or does not meet criteria for both clinical band radiological improvement , after more than 6 months of the child receiving an appropriate DR-TB regimen (with adherence > 80%)in the absence of IRIS

New patient whose sputum smear or culture is positive at 5 months or later during treatment. Also included in this definition are patients found to harbor a multidrug resistant strain at any point of time during the treatment

New patient who is culture or sputum smear microscopy positive at five months or later during treatment, or who is switched to category IV treatment because sputum culture revealed mdr-TB; (ii) A previously-treated patient who is culture or sputum smear microscopy positive at the end of the re-treatment regimen or who is switched to category IV treatment because sputum culture revealed mdr-TB

New patient who is sputum smear microscopy positive at 5 months or later during treatment, or who is switched to Category IV treatment because sputum turned out to be MDRTB. Previously-treated patient who is sputum smear microscopy positive at the end of his re-treatment or who is switched to Category IV treatment because sputum turned out to be MDRTB

Patient who is sputum smear positive at five months or later during treatment